PERCUTANEOUS PULMONARY ARTERY DRAINAGE DEVICE
20210244911 · 2021-08-12
Inventors
- Dongfang Wang (Lexington, KY, US)
- Joseph B. Zwischenberger (Lexington, KY, US)
- Guangfeng Zhao (Shenzhen, CN)
- Cherry Ballard-Croft (Lexington, KY, US)
Cpc classification
A61M60/109
HUMAN NECESSITIES
A61M25/0074
HUMAN NECESSITIES
A61M2025/0031
HUMAN NECESSITIES
A61M1/3666
HUMAN NECESSITIES
A61M25/003
HUMAN NECESSITIES
A61M2025/0004
HUMAN NECESSITIES
A61M1/3659
HUMAN NECESSITIES
A61M2205/0216
HUMAN NECESSITIES
International classification
Abstract
A multiple lumen device for percutaneous left ventricular unloading during venoarterial extracorporeal membrane oxygenation comprising: an expandable cage, an outer catheter, and an inner catheter, wherein a proximal end of the expandable cage is attached to the outer catheter and a distal end of the expandable cage is attached to the inner catheter, such that when the proximal end of the inner catheter is retracted, the cage moves from a compressed configuration to an expanded configuration is described. Also provided are methods for causing the blood of a subject to flow in a retrograde manner using a multiple lumen device.
Claims
1. A multiple lumen device, comprising: (a) an expandable cage having a proximal end and a distal end; (b) an outer catheter comprising a first lumen and having a proximal end and a distal end; (c) an inner catheter comprising a second lumen and a third lumen, and having a proximal end and a distal end, the inner catheter extending through the outer catheter and the expandable cage, and extending beyond the distal end of the expandable cage, wherein the proximal end of the expandable cage is attached to the outer catheter and the distal end of the expandable cage is attached to the inner catheter, such that when the proximal end of the inner catheter is retracted, the cage moves from a compressed configuration to an expanded configuration.
2. The device of claim 1, and further comprising a pressure monitor in fluid communication with the outer catheter for measuring pressure in the right atrium (RA).
3. The device of claim 1, and further comprising an inflatable balloon at the distal tip of and in fluid communication with the second and third lumens of the inner catheter.
4. The device of claim 3, and further comprising a syringe in fluid communication with the second lumen of the inner catheter for inflating the balloon.
5. The device of claim 3, and further comprising a pressure monitor in fluid communication with the third lumen of the inner catheter for measuring for measuring pressure in the pulmonary artery (PAP) and pulmonary artery wedge pressure (PCWP).
6. The device of claim 1, wherein the wire cage is comprised of super-elastic nitinol wire, stainless steel wire, super elastic polymer, or combinations thereof.
7. The device of claim 1, wherein at least two surgical grade threads are placed around the cage at equal distance from each other.
8. The device of claim 7, wherein the surgical grade threads are comprised of polyester, polypropylene, nylon, or combinations thereof.
9. The device of claim 1, where at least one of the outer catheter or the inner catheter is coated with polytetrafluoroethylene.
10. The device of claim 1, wherein the device is comprised of polyurethane, PVC, silicone, PFTE, polyisoprene, nitrile, or combinations thereof.
11. The device of claim 1, wherein the cage has a maximal expanded diameter from 12 mm to 15 mm.
12. A method for causing blood to flow in a retrograde manner from the pulmonary artery into the right atrium, comprising: (a) selecting a multiple lumen device comprising: (i) an expandable cage having a proximal end and a distal end; (ii) an outer catheter comprising a first lumen and having a proximal end and a distal end; (iii) an inner catheter comprising a second lumen and a third lumen, and having a proximal end and a distal end, the inner catheter extending through the outer catheter and the expandable cage, and extending beyond the distal end of the expandable cage, wherein the proximal end of the expandable cage is attached to the outer catheter and the distal end of the expandable cage is attached to the inner catheter, such that when the proximal end of the inner catheter is retracted, the cage moves from a compressed configuration to an expanded configuration; (b) percutaneously inserting the multiple lumen device into a blood vessel that leads to the heart; (c) continuing to insert the multiple lumen device until the distal end of the cage is through the pulmonary valve and into the pulmonary artery; (d) retracting the inner catheter until the cage is in an expanded configuration; (e) allowing the desired amount of blood to flow in a retrograde manner from the pulmonary artery into the right atrium; (f) extending the inner catheter until the cage is in a compressed configuration; and (g) removing the multiple lumen device from the blood vessel.
13. A multiple lumen device, comprising: (a) an expandable cage having a proximal end and a distal end; (b) an outer catheter comprising a first lumen and having a proximal end and a distal end; (c) an inner catheter comprising a second lumen and a third lumen, and having a proximal end and a distal end, the inner catheter extending through the outer catheter and the expandable cage, and extending beyond the distal end of the expandable cage, wherein at least one of the proximal end and the distal end of the expandable cage is attached to the inner catheter, such that when the proximal end of the inner catheter is retracted, the cage is collapsed within the outer catheter into a compressed configuration and when the proximal end of the outer catheter is retracted, the cage extends from the distal end of the outer catheter into an expanded configuration.
14. The device of claim 13, wherein both the proximal end and the distal end of the expandable cage are attached to the inner catheter.
15. The device of claim 13, wherein only one of the proximal end and the distal end of the expandable cage are attached to the inner catheter.
16. The device of claim 13, and further comprising a pressure monitor in fluid communication with the outer catheter for measuring pressure in the right atrium (RA).
17. The device of claim 13, and further comprising an inflatable balloon at the distal tip of and in fluid communication with at least one of the second and third lumens of the inner catheter.
18. The device of claim 17, and further comprising a syringe in fluid communication with the second lumen of the inner catheter for inflating the balloon.
19. The device of claim 17, and further comprising a pressure monitor in fluid communication with the third lumen of the inner catheter for measuring for measuring pressure in the pulmonary artery (PAP) and pulmonary artery wedge pressure (PCWP).
20. The device of claim 13, wherein the cage has a maximal expanded diameter from 12 mm to 15 mm.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS
[0032] The details of one or more embodiments of the presently-disclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and other embodiments, will be evident to those of ordinary skill in the art after a study of the information provided in this document. The information provided in this document, and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood therefrom. In case of conflict, the specification of this document, including definitions, will control.
[0033] Each example is provided by way of explanation of the present disclosure and is not a limitation thereon. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made to the teachings of the present disclosure without departing from the scope of the disclosure. For instance, features illustrated or described as part of one embodiment can be used with another embodiment to yield a still further embodiment.
[0034] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic(s) or limitation(s) and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
[0035] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the presently-disclosed subject matter belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the presently-disclosed subject matter, representative methods, devices, and materials are now described.
[0036] Following long-standing patent law convention, the terms “a”, “an”, and “the” refer to “one or more” when used in this application, including the claims. For example, reference to “a device” includes a plurality of devices, and so forth.
[0037] Unless otherwise indicated, all numbers expressing quantities, properties, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”. Accordingly, unless indicated to the contrary, the numerical parameters set forth in this specification and claims are approximations that can vary depending upon the desired properties sought to be obtained by the presently-disclosed subject matter.
[0038] As used herein, the term “about,” when referring to a value or to an amount of mass, length, width, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
[0039] As used herein, ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0040] As used herein, the terms “about” and “approximately” are used interchangeably and carry the same meaning.
[0041] While the following terms used herein are believed to be well understood by one of ordinary skill in the art, definitions are set forth to facilitate explanation of the presently-disclosed subject matter.
[0042] The terms “subject” or “subject in need thereof” refer to a target in need of intervention, wherein the subject optionally displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein disclosed methods can be a human, non-human primate, horse, pig, dog, sheep, goat, or cow. The term “subject” does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. A “subject” refers to a subject afflicted with a disease or disorder. The term “subject” includes human and veterinary subjects.
[0043] The terms “treatment” or “treating” refer to the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder and/or resulting symptoms of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
[0044] The present invention relates to a device the left ventricle to be unloaded during venoarterial extracorporeal membrane oxygenation (ECMO) in a minimally-evasive manner. Accordingly, such a device can be useful, for example, to facilitate myocardial recovery after cardiogenic shock.
[0045] Uniquely, the device keeps both the pulmonary artery valve and tricuspid valves open simultaneously by threading through both the pulmonary artery valve and tricuspid valves, and when the wire cage is expanded, allowing blood to flow in a retrograde manner from the PA toward the right atrium for improved ECMO drainage. The device therefore creates lower pulmonary artery pressure, decreases blood flow from pulmonary artery to left atrium, and allows retrograde blood flow from the left atrium to the pulmonary artery to unload the left ventricle. Because the operator has fine control over the expansion of the metal cage in both valves, it allows for the appropriate amount of ECMO drainage can occur.
[0046] In some embodiments, as illustrated in
[0047] Referring to
[0048]
[0049] Referring to
[0050] Referring to
[0051] Referring to
[0052] Referring to
[0053] In this manner, and with continued reference to
[0054] According to one or more of the embodiments disclosed herein, the device is formed by polyurethane (PU) dip molding, synthetic polyisoprene dip molding, silicone dip molding, polytetrafluoropolymer molding, polyvinyl chloride molding, or nitrile dip molding.
[0055] According to other embodiments disclosed herein, the outer surface of the inner catheter and/or the inner surface of the outer catheter may be coated with polytetrafluoroethylene to decrease the sliding friction for easy metal cage expansion.
[0056] In another embodiment disclosed herein, the cage has a maximal expanded size of about 12 mm.
[0057] The catheter and connecter is formed from any suitable material for insertion and/or fixation within an individual's body. Accordingly, as will be appreciated by those skilled in the art, the material of the device may vary. Suitable materials for the device include, but are not limited to, polyurethane, PVC, silicone, PTFE, polyisoprene, nitrile, or a combination thereof.
[0058] The seal for the connection between the inner and outer catheters may be sealed by a number of suitable materials, including but not limited to silicone membrane sleeve, PVC, PTFE, polyisoprene, nitrile, or combination thereof.
[0059] The wire cage is woven to provide strength and elasticity. Accordingly it will be appreciated by those skilled in the art, the material of the wire cage may vary. Suitable materials for the wire cage include, but are not limited to, super-elastic nitinol wire, stainless steel wire, super elastic polymer, or combinations thereof.
[0060] At least 2 approximately 0.1 mm surgical grade threads are placed around the wire cage to maintain an even cylindrical shape and restrain the maximal diameter of the expanded cage to approximately 15 mm. Suitable materials for the surgical grade threads include, but are not limited to, polyester, polypropylene, nylon or combinations thereof.
INCORPORATION BY REFERENCE
[0061] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference
[0062] It will be understood that various details of the presently disclosed subject matter can be changed without departing from the scope of the subject matter disclosed herein. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.
REFERENCES
[0063] 1. Jeger, R. V., et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Annals of internal medicine 149, 618-626 (2008). [0064] 2. Hochman, J. S., et al. Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J. Am. Coll. Cardiol. 36, 1063 (2000). [0065] 3. Goldberg, R. J., Spencer, F. A., Gore, J. M., Lessard, D. & Yarzebski, J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119, 1211-1219 (2009). [0066] 4. Thiagaraj an, R. R., et al. Extracorporeal Life Support Organization Registry International Report 2016. Asaio j 63, 60-67 (2017). [0067] 5. Truby, L. K., et al. Incidence and Implications of Left Ventricular Distention During Venoarterial Extracorporeal Membrane Oxygenation Support. ASAIO J 63, 257-265 (2017). [0068] 6. Stretch, R., Sauer, C. M., Yuh, D. D. & Bonde, P. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol 64, 1407-1415 (2014). [0069] 7. Thiele, H., et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367, 1287-1296 (2012). [0070] 8. Miller, P. E., Solomon, M. A. & McAreavey, D. Advanced Percutaneous Mechanical Circulatory Support Devices for Cardiogenic Shock. Crit Care Med 45, 1922-1929 (2017). [0071] 9. Kar, B., Gregoric, I. D., Basra, S. S., Idelchik, G. M. & Loyalka, P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 57, 688-696 (2011). [0072] 10. Ouweneel, D. M., Eriksen, E., Seyfarth, M. & Henriques, J. P. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock: Meta-Analysis. J Am Coll Cardiol 69, 358-360 (2017). [0073] 11. Shishehbor, M. H., et al. Cardiogenic shock: From ECMO to Impella and beyond. Cleve Clin J Med 84, 287-295 (2017). [0074] 12. Shah, M., et al. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clinical research in cardiology: official journal of the German Cardiac Society (2017). [0075] 13. Schmack, B., et al. Extracorporeal life support with left ventricular decompression-improved survival in severe cardiogenic shock: results from a retrospective study. Peer J 5, e3813 (2017). [0076] 14. Pappalardo, F., et al. Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 19, 404-412 (2017). [0077] 15. Beurtheret, S., Mordant, P., Pavie, A. & Leprince, P. Impella and extracorporeal membrane oxygenation: a demanding combination. ASAIO J 58, 291-293 (2012). [0078] 16. Barbone, A., Malvindi, P. G., Ferrara, P. & Tarelli, G. Left ventricle unloading by percutaneous pigtail during extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 13, 293-295 (2011). [0079] 17. Hong, T. H., et al. Initial Experience of Transaortic Catheter Venting in Patients with Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock. ASAIO J 62, 117-122 (2016). [0080] 18. Kotani, Y., et al. Left atrial decompression during venoarterial extracorporeal membrane oxygenation for left ventricular failure in children: current strategy and clinical outcomes. Artif Organs 37, 29-36 (2013). [0081] 19. Hacking, D. F., et al. Elective decompression of the left ventricle in pediatric patients may reduce the duration of venoarterial extracorporeal membrane oxygenation. Artif Organs 39, 319-326 (2015). [0082] 20. Bernhardt, A. M., et al. Percutaneous left atrial unloading to prevent pulmonary oedema and to facilitate ventricular recovery under extracorporeal membrane oxygenation therapy. Interact Cardiovasc Thorac Surg (2017). [0083] 21. Aiyagari, R. M., Rocchini, A. P., Remenapp, R. T. & Graziano, J. N. Decompression of the left atrium during extracorporeal membrane oxygenation using a transseptal cannula incorporated into the circuit. Crit Care Med 34, 2603-2606 (2006). [0084] 22. Baruteau, A. E., et al. Percutaneous balloon atrial septostomy on top of venoarterial extracorporeal membrane oxygenation results in safe and effective left heart decompression. European heart journal. Acute cardiovascular care (2016). [0085] 23. Lin, Y. N., et al. Atrial Septostomy for Left Atrial Decompression During Extracorporeal Membrane Oxygenation by Inoue Balloon Catheter. Circ J 81, 1419-1423 (2017). [0086] 24. von Segesser, L. K., Kwang, K., Tozzi, P., Horisberger, J. & Dembitsky, W. A simple way to decompress the left ventricle during venoarterial bypass. Thorac Cardiovasc Surg 56, 337-341 (2008). [0087] 25. Fouilloux, V., Lebrun, L., Mace, L. & Kreitmann, B. Extracorporeal membranous oxygenation and left atrial decompression: a fast and minimally invasive approach. Ann Thorac Surg 91, 1996-1997 (2011). [0088] 26. Avalli, L., et al. Percutaneous left-heart decompression during extracorporeal membrane oxygenation: an alternative to surgical and transeptal venting in adult patients. ASAIO J 57, 38-40 (2011). [0089] 27. Foti, G., et al. Cardiopulmonary bypass through peripheral cannulation with percutaneous decompression of the left heart in a model of severe myocardial failure. Asaio j 43, 927-931 (1997). [0090] 28. Kolobow, T., Rossi, F., Borelli, M. & Foti, G. Long-term closed chest partial and total cardiopulmonary bypass by peripheral cannulation for severe right and/or left ventricular failure, including ventricular fibrillation. The use of a percutaneous spring in the pulmonary artery position to decompress the left heart. ASAIO Trans 34, 485-489 (1988). [0091] 29. Rossi, F., Kolobow, T., Foti, G., Borelli, M. & Mandava, S. Long-term cardiopulmonary bypass by peripheral cannulation in a model of total heart failure. The decompression of the left heart through a percutaneous helical spring positioned within the lumen of the tricuspid and pulmonary artery valves. J. Thorac. Cardiovasc. Surg. 100, 914 (1990). [0092] 30. Kolobow, T. Method for improved use of heart/lung machine Vol. U.S. Pat. No. 4,889,137 (The United States Of America As Represented By The Department Of Health And Human Services, 1989). [0093] 31. Wang, D. & Zwischenberger, J. B. Single expandable double lumen cannula assembly for veno-venous ECMO in USPTO (ed. USPTO) (The University of Texas System USA, 2009). [0094] 32. Evans, S. Patients Up and About With Portable, Artificial Lung. (ABC News, Apr. 2, 2009). [0095] 33. Chimot, L., et al. Avalon(c) bicaval dual-lumen cannula for venovenous extracorporeal membrane oxygenation: survey of cannula use in France. Asaio j 59, 157-161 (2013). [0096] 34. Reeb, J., Falcoz, P. E., Santelmo, N. & Massard, G. Double lumen bi-cava cannula for veno-venous extracorporeal membrane oxygenation as bridge to lung transplantation in non-intubated patient. Interact Cardiovasc Thorac Surg (2011). [0097] 35. Abrams, D., et al. Insertion of bicaval dual-lumen cannula via the left internal jugular vein for extracorporeal membrane oxygenation. Asaio J 58, 636-637 (2012). [0098] 36. Dolch, M. E., et al. Transesophageal echocardiography-guided technique for extracorporeal membrane oxygenation dual-lumen catheter placement. Asaio J 57, 341-343 (2011). [0099] 37. Javidfar, J., et al. Use of bicaval dual-lumen catheter for adult venovenous extracorporeal membrane oxygenation. Ann Thorac Surg 91, 1763-1768; discussion 1769 (2011). [0100] 38. Wang, D., et al. Wang-Zwische double lumen cannula-toward a percutaneous and ambulatory paracorporeal artificial lung. Asaio j 54, 606-611 (2008). [0101] 39. Zhou, X., et al. Long-term support with an ambulatory percutaneous paracorporeal artificial lung. J Heart Lung Transplant 31, 648-654 (2012). [0102] 40. Hayes, D., Jr., Kukreja, J., Tobias, J. D., Ballard, H. O. & Hoopes, C. W. Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation. J Cyst Fibros 11, 40-45 (2012). [0103] 41. Camboni, D., Philipp, A., Mueller, T. & Schmid, C. An important step toward ambulatory veno-venous extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 144, 282-283; author reply 283-284 (2012). [0104] 42. Garcia, J. P., et al. Ambulatory veno-venous extracorporeal membrane oxygenation: innovation and pitfalls. J Thorac Cardiovasc Surg 142, 755-761 (2011). [0105] 43. Garcia, J. P., Iacono, A., Kon, Z. N. & Griffith, B. P. Ambulatory extracorporeal membrane oxygenation: a new approach for bridge-to-lung transplantation. J Thorac Cardiovasc Surg 139, e137-139 (2010). [0106] 44. Camboni, D., et al. Extracorporeal membrane oxygenation by single-vessel access in adults: advantages and limitations. ASAIO J 58, 616-621 (2012). [0107] 45. Turner, D. A., et al. Ambulatory ECMO as a Bridge to Lung Transplant in a Previously Well Pediatric Patient With ARDS. Pediatrics (2014). [0108] 46. Hayes, D., Jr., et al. Tracheostomy in adolescent patients bridged to lung transplantation with ambulatory venovenous extracorporeal membrane oxygenation. J Artif Organs 17, 103-105 (2014). [0109] 47. Hayes, D., Jr., et al. Pediatric Ambulatory ECMO. Lung (2014). [0110] 48. Wang, D., et al. Development of a Double-Lumen Cannula for a Percutaneous RVAD. ASAIO J 61, 397-402 (2015). [0111] 49. Condemi, F., et al. Percutaneous Double Lumen Cannula for Right Ventricle Assist Device System: A Computational Fluid Dynamics Study. Biocybern Biomed Eng 36, 482-490 (2016). [0112] 50. Kazui, T., et al. Minimally invasive approach for percutaneous CentriMag right ventricular assist device support using a single PROTEKDuo Cannula. Journal of cardiothoracic surgery 11, 123 (2016).